Solve Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 33

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $321M

  • Investors
  • 15

Solve Therapeutics General Information

Description

Operator of a drug development platform intended to develop novel antibody-drug conjugates. The company is developing bispecific therapeutics engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics, enabling medical professionals to help patients improve their lives and fulfill some unmet needs.

Contact Information

Website
www.solvetx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1025 Alameda De Las Pulgas
  • Suite 122
  • Belmont, CA 94002
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1025 Alameda De Las Pulgas
  • Suite 122
  • Belmont, CA 94002
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Solve Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 17-Nov-2025 $321M Completed Clinical Trials - Phase 1
2. Early Stage VC 17-Dec-2021 Completed Startup
1. University Spin-Out 01-Jan-2021 Completed Startup
To view Solve Therapeutics’s complete valuation and funding history, request access »

Solve Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Solve Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Solve Therapeutics Patents

Solve Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026217653-A1 Drug-linker compounds Pending 09-Apr-2025
WO-2026178013-A1 Conjugates and uses thereof Pending 18-Feb-2025
WO-2026178014-A1 Conjugates and uses thereof Pending 18-Feb-2025
WO-2026174205-A1 Adozelesin based antibody drug conjugates and uses thereof Pending 14-Feb-2025
WO-2026173867-A1 Conjugates and uses thereof Pending 12-Feb-2025 A61K47/6889
To view Solve Therapeutics’s complete patent history, request access »

Solve Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Solve Therapeutics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Ally Bridge Group Growth/Expansion Minority
AyurMaya Capital PE/Buyout Minority
Balyasny Asset Management Hedge Fund Minority
You’re viewing 5 of 15 investors. Get the full list »

Solve Therapeutics Acquisitions (1)

Solve Therapeutics’s most recent deal was a Merger/Acquisition with Cereius. The deal was made on 22-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cereius 22-Jun-2023 Merger/Acquisition Drug Discovery
To view Solve Therapeutics’s complete acquisitions history, request access »

Solve Therapeutics FAQs

  • When was Solve Therapeutics founded?

    Solve Therapeutics was founded in 2021.

  • Where is Solve Therapeutics headquartered?

    Solve Therapeutics is headquartered in Belmont, CA.

  • What is the size of Solve Therapeutics?

    Solve Therapeutics has 33 total employees.

  • What industry is Solve Therapeutics in?

    Solve Therapeutics’s primary industry is Drug Discovery.

  • Is Solve Therapeutics a private or public company?

    Solve Therapeutics is a Private company.

  • What is the current valuation of Solve Therapeutics?

    The current valuation of Solve Therapeutics is .

  • What is Solve Therapeutics’s current revenue?

    The current revenue for Solve Therapeutics is .

  • How much funding has Solve Therapeutics raised over time?

    Solve Therapeutics has raised $385M.

  • Who are Solve Therapeutics’s investors?

    Abingworth, Alexandria Venture Investments, Ally Bridge Group, AyurMaya Capital, and Balyasny Asset Management are 5 of 15 investors who have invested in Solve Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process